A detailed history of Goldman Sachs Group Inc transactions in Savara Inc stock. As of the latest transaction made, Goldman Sachs Group Inc holds 696,807 shares of SVRA stock, worth $2.18 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
696,807
Previous 287,441 142.42%
Holding current value
$2.18 Million
Previous $1.16 Million 155.09%
% of portfolio
0.0%
Previous 0.0%

Shares

19 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$3.96 - $5.07 $1.62 Million - $2.08 Million
409,366 Added 142.42%
696,807 $2.95 Million
Q2 2024

Aug 13, 2024

BUY
$3.66 - $5.34 $521,773 - $761,275
142,561 Added 98.4%
287,441 $1.16 Million
Q1 2024

May 15, 2024

BUY
$4.19 - $5.59 $74,079 - $98,831
17,680 Added 13.9%
144,880 $721,000
Q4 2023

Feb 13, 2024

BUY
$3.18 - $4.9 $123,686 - $190,585
38,895 Added 44.05%
127,200 $597,000
Q3 2023

May 14, 2024

SELL
$2.97 - $3.88 $115,518 - $150,912
-38,895 Reduced 30.58%
88,305 $333,000
Q3 2023

Nov 14, 2023

BUY
$2.97 - $3.88 $1,761 - $2,300
593 Added 0.68%
88,305 $333,000
Q2 2023

May 14, 2024

SELL
$1.69 - $3.24 $113,860 - $218,288
-67,373 Reduced 43.44%
87,712 $279,000
Q2 2023

Aug 14, 2023

SELL
$1.69 - $3.24 $113,860 - $218,288
-67,373 Reduced 43.44%
87,712 $279,000
Q1 2023

May 14, 2024

BUY
$1.6 - $2.82 $221,841 - $390,995
138,651 Added 843.68%
155,085 $302,000
Q1 2023

May 11, 2023

BUY
$1.6 - $2.82 $221,841 - $390,995
138,651 Added 843.68%
155,085 $302,000
Q4 2022

May 14, 2024

SELL
$1.11 - $1.64 $19,598 - $28,955
-17,656 Reduced 51.79%
16,434 $25,000
Q4 2022

Feb 13, 2023

SELL
$1.11 - $1.64 $19,598 - $28,955
-17,656 Reduced 51.79%
16,434 $25,000
Q3 2022

May 14, 2024

SELL
$1.36 - $1.88 $24,701 - $34,146
-18,163 Reduced 34.76%
34,090 $53,000
Q3 2022

Nov 10, 2022

SELL
$1.36 - $1.88 $24,701 - $34,146
-18,163 Reduced 34.76%
34,090 $0
Q2 2022

May 14, 2024

SELL
$1.1 - $1.58 $82,441 - $118,416
-74,947 Reduced 58.92%
52,253 $79,000
Q2 2022

Aug 15, 2022

SELL
$1.1 - $1.58 $58,976 - $84,711
-53,615 Reduced 50.64%
52,253 $79,000
Q1 2022

May 16, 2022

SELL
$1.05 - $1.36 $569 - $737
-542 Reduced 0.51%
105,868 $139,000
Q4 2021

Feb 14, 2022

BUY
$1.04 - $1.34 $35,589 - $45,856
34,221 Added 47.4%
106,410 $132,000
Q3 2021

Nov 10, 2021

BUY
$1.18 - $1.64 $85,183 - $118,389
72,189 New
72,189 $100,000

Others Institutions Holding SVRA

About Savara Inc


  • Ticker SVRA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 114,043,000
  • Market Cap $357M
  • Description
  • Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. Its lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase III development stage for the treatment of autoimmune pulmonary alveolar proteinosis. The company is headquartered in Austin, Texas.
More about SVRA
Track This Portfolio

Track Goldman Sachs Group Inc Portfolio

Follow Goldman Sachs Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Goldman Sachs Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Goldman Sachs Group Inc with notifications on news.